Total Skin Electron Beam for Primary XXXX .

@entity1 @entity4888 @entity137 @entity706 @entity4889 @entity784
PURPOSE: Recent trials with low-dose total skin electron beam (TSEB) therapy demonstrated encouraging results for treating primary @entity784 (PCTCL). In this study, we assessed the feasibility of different radiation doses and estimated survival rates of different pathologic entities and stages. METHODS AND MATERIALS: We retrospectively identified 45 @entity1 with PCTCL undergoing TSEB therapy between 2000 and 2015. Clinical characteristics, treatment outcomes, and @entity137 were assessed. RESULTS: A total of 49 courses of TSEB therapy were administered to the 45 @entity1 . There were 26 pathologically confirmed cases of @entity4888 ( @entity4888 ) @entity706 , 10 cases of @entity4889 ( @entity4889 ), and 9 non- @entity4888 / @entity4889 PCTCL @entity1 . In the @entity4888 @entity1 , the overall response rate (ORR) was 92% (50% complete remission [CR]), 70% ORR in @entity4889 @entity1 (50% CR), and 89% ORR in non- @entity4888 / @entity4889 @entity1 (78% CR). The ORR for @entity4888 / @entity4889 @entity1 treated with conventional dose (30-36  Gy) regimens was 92% (63% CR) and 75% (25% CR) for low-dose (<30-Gy) regimens (P=.09). In @entity4888 @entity1 , the overall survival (OS) was 77  months with conventional dose regimens versus 14  months with low-dose regimens (P=.553). In @entity4889 @entity1 , the median OS was 48 versus 16  months (P=.219), respectively. Median event-free survival (EFS) for @entity4888 in conventional dose @entity1 versus low-dose @entity1 was 15 versus 8  months, respectively (P=.264) and 19 versus 3  months for @entity4889 @entity1 (P=.457). Low-dose regimens had shorter treatment time (P=.009) and lower grade 2 adverse events (P=.043). A second TSEB course was administered in 4  @entity4888 @entity1 with 100% ORR. There is a possible prognostic impact of supplemental/boost radiation (P<.001); adjuvant treatment (P<.001) and radiation tolerability (P=.021) were detected. CONCLUSIONS: TSEB therapy is an efficacious treatment modality in the treatment of several forms of @entity784 . There is a nonsignificant trend to higher and longer clinical benefit for @entity4888 and @entity4889 @entity1 receiving conventional dose. Low-dose TSEB regimens are well tolerated and achieve short-term palliation.
